Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Page 1
Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension.
Harbaum L, Rhodes CJ, Wharton J, Lawrie A, Karnes JH, Desai AA, Nichols WC, Humbert M, Montani D, Girerd B, Sitbon O, Boehm M, Novoyatleva T, Schermuly RT, Ghofrani HA, Toshner M, Kiely DG, Howard LS, Swietlik EM, Gräf S, Pietzner M, Morrell NW, Wilkins MR; U.K. National Institute for Health Research BioResource Rare Diseases Consortium, U.K. Pulmonary Arterial Hypertension Cohort Study Consortium, and U.S. Pulmonary Arterial Hypertension Biobank Consortium. Harbaum L, et al. Am J Respir Crit Care Med. 2022 Jun 15;205(12):1449-1460. doi: 10.1164/rccm.202109-2106OC. Am J Respir Crit Care Med. 2022. PMID: 35394406 Free PMC article.
Measurements and Main Results: From 4,152 annotated plasma proteins, levels of 208 differed between patients with PAH and healthy subjects, and 49 predicted long-term survival. MR based on cis-pQTL located in proximity to the encoding gene for proteins that were prognostic …
Measurements and Main Results: From 4,152 annotated plasma proteins, levels of 208 differed between patients with PAH and healthy subjects, …
Application of the REVEAL risk score calculator 2.0 in the CHEST study.
Benza RL, Farber HW, Frost AE, Ghofrani HA, Corris PA, Lambelet M, Nikkho S, Meier C, Hoeper MM. Benza RL, et al. Among authors: corris pa. Respir Med. 2022 Apr-May;195:106783. doi: 10.1016/j.rmed.2022.106783. Epub 2022 Mar 1. Respir Med. 2022. PMID: 35256218 Free article.
BACKGROUND: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmo …
BACKGROUND: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry t …
Application of the REVEAL risk score calculator 2.0 in the PATENT study.
Benza RL, Farber HW, Frost AE, Ghofrani HA, Corris PA, Lambelet M, Nikkho S, Meier C, Hoeper MM. Benza RL, et al. Among authors: corris pa. Int J Cardiol. 2021 Jun 1;332:189-192. doi: 10.1016/j.ijcard.2021.03.034. Epub 2021 Mar 17. Int J Cardiol. 2021. PMID: 33744348 Free article.
CONCLUSIONS: These data suggest that RRS 2.0 has clinical utility in predicting long-term outcomes and monitoring treatment response in patients with PAH....
CONCLUSIONS: These data suggest that RRS 2.0 has clinical utility in predicting long-term outcomes and monitoring treatment response …
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Simonneau G, Ghofrani HA, Corris PA, Rosenkranz S, Grünig E, White J, McLaughlin VV, Langleben D, Meier C, Busse D, Kleinjung F, Benza RL. Simonneau G, et al. Among authors: corris pa. Pulm Circ. 2020 Dec 9;10(4):2045894020973124. doi: 10.1177/2045894020973124. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33354316 Free PMC article.
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension and an i …
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term …
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.
Rhodes CJ, Otero-Núñez P, Wharton J, Swietlik EM, Kariotis S, Harbaum L, Dunning MJ, Elinoff JM, Errington N, Thompson AAR, Iremonger J, Coghlan JG, Corris PA, Howard LS, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort SJ, Desai AA, Humbert M, Nichols WC, Southgate L, Trégouët DA, Trembath RC, Prokopenko I, Gräf S, Morrell NW, Wang D, Lawrie A, Wilkins MR. Rhodes CJ, et al. Among authors: corris pa. Am J Respir Crit Care Med. 2020 Aug 15;202(4):586-594. doi: 10.1164/rccm.202003-0510OC. Am J Respir Crit Care Med. 2020. PMID: 32352834 Free PMC article.
The RNA model score was associated with disease severity and long-term survival (P = 4.66 10(-6)) in PAH. MR detected an association between SMAD5 levels and PAH disease susceptibility (odds ratio, 0.317; 95% confidence interval, 0.129-0.776; P = 0.012).Conclusions: A whol …
The RNA model score was associated with disease severity and long-term survival (P = 4.66 10(-6)) in PAH. MR detected an association …
Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
Peacock AJ, Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JSR, Howard LS, Pepke-Zaba J, Sheares KKK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA. Peacock AJ, et al. Among authors: corris pa. Pulm Circ. 2020 Mar 30;10(1):2045894020914851. doi: 10.1177/2045894020914851. eCollection 2020 Jan-Mar. Pulm Circ. 2020. PMID: 32284847 Free PMC article.
This survival was significantly worse in 'IPAH (lung disease) ' even after adjusting for age, gender, smoking history, comorbidities and haemodynamics. 'IPAH (lung disease) ' patients had similar short-term improvement in six-minute walk distance with anti-pulmonary arteri …
This survival was significantly worse in 'IPAH (lung disease) ' even after adjusting for age, gender, smoking history, comorbidities and hae …
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main …
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of …
Long-term effect of azithromycin in bronchiolitis obliterans syndrome.
Gan CT, Ward C, Meachery G, Lordan JL, Fisher AJ, Corris PA. Gan CT, et al. Among authors: corris pa. BMJ Open Respir Res. 2019 Oct 15;6(1):e000465. doi: 10.1136/bmjresp-2019-000465. eCollection 2019. BMJ Open Respir Res. 2019. PMID: 31673366 Free PMC article. Clinical Trial.
Survival of patients with early BOS was similar to late-onset BOS (log-rank test p=0.74). DISCUSSION: Long-term treatment with azithromycin slows down the progression of BOS, although the effect of TLI may affect the observed attenuation of FEV(1) decline. BOS progression …
Survival of patients with early BOS was similar to late-onset BOS (log-rank test p=0.74). DISCUSSION: Long-term treatment with azithr …
Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.
Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Sithamparanathan S, et al. Among authors: corris pa. J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014. Epub 2016 Dec 31. J Heart Lung Transplant. 2017. PMID: 28190786
BACKGROUND: Portopulmonary hypertension (PoPH) is a rare condition associated with poor survival, and the effect of modern therapies that target pulmonary arterial hypertension (PAH) on long-term outcome is unknown. This study investigated the baseline characteristics and …
BACKGROUND: Portopulmonary hypertension (PoPH) is a rare condition associated with poor survival, and the effect of modern therapies that ta …
Observational study of lung transplant recipients surviving 20 years.
Sithamparanathan S, Thirugnanasothy L, Clark S, Dark JH, Fisher AJ, Gould KF, Hasan A, Lordan JL, Meachery G, Parry G, Corris PA. Sithamparanathan S, et al. Among authors: corris pa. Respir Med. 2016 Aug;117:103-8. doi: 10.1016/j.rmed.2016.06.008. Epub 2016 Jun 7. Respir Med. 2016. PMID: 27492519 Free article. Clinical Trial.
BACKGROUND: Lung transplant recipients have reduced long-term survival compared with other solid organ recipients. There is a lack of published data on the characteristics of very long term survivors. ...CONCLUSIONS: In our experience, 20-year survivors of lung tran …
BACKGROUND: Lung transplant recipients have reduced long-term survival compared with other solid organ recipients. There is a lack of …
32 results